EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs

Daniel Tobias Michaeli iD, Thomas Michaeli iD, Sebastian Albers iD, Julia Caroline Michaeli iD

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01081-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2024. Verfasst von Daniel Tobias Michaeli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germa…. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents, United States Food and Drug Administration. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universitätsklinikum Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination. OBJECTIVE: To identify and quantify factors associated with patient accrual in trials leading to the US Food and Drug Administration (FDA) approval of new cancer drugs. DATA: All anti-cancer drugs with FDA approval were identified in the Drugs@FDA database (2000-2022). Data on drug indication's background-, treatment-, disease-, and trial-related factors were collected from FDA labels, clinicaltrials.gov, and the Global Burden of Disease study. The association between patient accrual and collected variables was assessed in Poisson regression models reporting adjusted rate ratios (aRR). RESULTS: We identified 170 drugs with approval in 455 cancer indications on the basis of 292 randomized and 163 single-arm trials. Among randomized trials, median enrollment per month was 38 patients (interquartile range [IQR]: 26-54) for non-orphan, 21 (IQR: 15-38, aRR 0.88, p = 0.361) for common orphan, 20 (IQR: 10-35, aRR 0.73, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsUnited States Food and Drug AdministrationHumansUnited StatesNeoplasmsClinical Trials as Topic

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany. danielmichaeli@yahoo.com.
  • Department of Personalized Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
  • Division of Personalized Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Trauma Surgery, Klinikum Rechts Der Isar, Technical University of Munich, Munich, Germany.
  • Department of Obstetrics and Gynaecology, LMU University Hospital, LMU Munich, Munich, Germany.

ORCID-Profile: Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli

Förderung

  • Universitätsklinikum Heidelberg

Zitieren

APA

Michaeli, D. T., Michaeli, T., Albers, S., & Michaeli, J. C. (2024). Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. Targeted Oncology. https://doi.org/10.1007/s11523-024-01081-w

Vancouver

Michaeli DT, Michaeli T, Albers S, Michaeli JC. Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. Targeted Oncology. 2024. doi:10.1007/s11523-024-01081-w

BibTeX
@article{Michaeli2024,
  author = {Michaeli, Daniel Tobias and Michaeli, Thomas and Albers, Sebastian and Michaeli, Julia Caroline},
  title = {Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01081-w}
}
Kostenlos starten →